ZA202206835B - Method for purifying biologically active peptide by using protein a affinity chromatography - Google Patents
Method for purifying biologically active peptide by using protein a affinity chromatographyInfo
- Publication number
- ZA202206835B ZA202206835B ZA2022/06835A ZA202206835A ZA202206835B ZA 202206835 B ZA202206835 B ZA 202206835B ZA 2022/06835 A ZA2022/06835 A ZA 2022/06835A ZA 202206835 A ZA202206835 A ZA 202206835A ZA 202206835 B ZA202206835 B ZA 202206835B
- Authority
- ZA
- South Africa
- Prior art keywords
- biologically active
- active peptide
- protein
- affinity chromatography
- containing biologically
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 238000001042 affinity chromatography Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 101001057612 Homo sapiens Dual specificity protein phosphatase 5 Proteins 0.000 abstract 1
- 102000043381 human DUSP5 Human genes 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
- B01D15/166—Fluid composition conditioning, e.g. gradient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention provides a method for purifying an Fc-containing biologically active peptide mixture by using an affinity column comprising an affinity matrix that contains a protein A ligand, the mixture comprising a first Fc-containing biologically active peptide and a second Fc-containing biologically active peptide, wherein the second Fc-containing biologically active peptide comprises at least one more human VH3 domain than the first Fc-containing biologically active peptide. According to the purification method, biologically active peptides having the same or similar structures can be precisely separated with high purity, while process simplification is achieved.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962953687P | 2019-12-26 | 2019-12-26 | |
US201962953685P | 2019-12-26 | 2019-12-26 | |
KR20200173808 | 2020-12-11 | ||
PCT/IB2020/062434 WO2021130717A1 (en) | 2019-12-26 | 2020-12-24 | Method for purifying biologically active peptide by using protein a affinity chromatography |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA202206835B true ZA202206835B (en) | 2023-11-29 |
Family
ID=76574052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2022/06835A ZA202206835B (en) | 2019-12-26 | 2022-06-20 | Method for purifying biologically active peptide by using protein a affinity chromatography |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230212217A1 (en) |
EP (1) | EP4141025A4 (en) |
JP (1) | JP2023507923A (en) |
KR (1) | KR20210092280A (en) |
CN (1) | CN115003695A (en) |
AU (1) | AU2020414489A1 (en) |
BR (1) | BR112022011993A2 (en) |
CA (1) | CA3163017A1 (en) |
IL (1) | IL293845A (en) |
MX (1) | MX2022006972A (en) |
WO (1) | WO2021130717A1 (en) |
ZA (1) | ZA202206835B (en) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
KR20120027055A (en) | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
EP3401337A1 (en) * | 2012-09-25 | 2018-11-14 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
NZ720161A (en) * | 2013-11-04 | 2022-07-29 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
AR101262A1 (en) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | PURIFICATION PLATFORM FOR Bispecific Antibodies |
GB201506868D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
WO2019094608A1 (en) | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
CN111886251A (en) | 2017-12-14 | 2020-11-03 | Abl生物公司 | Bispecific antibodies against A-SYN/IGF1R and uses thereof |
-
2020
- 2020-12-24 AU AU2020414489A patent/AU2020414489A1/en active Pending
- 2020-12-24 MX MX2022006972A patent/MX2022006972A/en unknown
- 2020-12-24 JP JP2022534158A patent/JP2023507923A/en active Pending
- 2020-12-24 EP EP20908197.5A patent/EP4141025A4/en active Pending
- 2020-12-24 CN CN202080089549.6A patent/CN115003695A/en active Pending
- 2020-12-24 BR BR112022011993A patent/BR112022011993A2/en not_active Application Discontinuation
- 2020-12-24 WO PCT/IB2020/062434 patent/WO2021130717A1/en active Application Filing
- 2020-12-24 CA CA3163017A patent/CA3163017A1/en active Pending
- 2020-12-24 KR KR1020217018612A patent/KR20210092280A/en not_active Application Discontinuation
- 2020-12-24 IL IL293845A patent/IL293845A/en unknown
- 2020-12-24 US US17/789,163 patent/US20230212217A1/en active Pending
-
2022
- 2022-06-20 ZA ZA2022/06835A patent/ZA202206835B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4141025A4 (en) | 2024-04-24 |
BR112022011993A2 (en) | 2022-09-20 |
US20230212217A1 (en) | 2023-07-06 |
WO2021130717A1 (en) | 2021-07-01 |
KR20210092280A (en) | 2021-07-23 |
JP2023507923A (en) | 2023-02-28 |
MX2022006972A (en) | 2022-08-04 |
EP4141025A1 (en) | 2023-03-01 |
IL293845A (en) | 2022-08-01 |
CN115003695A (en) | 2022-09-02 |
CA3163017A1 (en) | 2021-07-01 |
AU2020414489A1 (en) | 2022-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072863L (en) | Procedure for Purifying FSH | |
BR112018003127A2 (en) | fkpa purification and uses thereof to produce recombinant polypeptides | |
SG10201908027QA (en) | Use of alkaline washes during chromatography to remove impurities | |
NZ587511A (en) | Purified lymphotoxin-beta-receptor immunoglobulin fusion proteins and methods of their purification | |
MX2020003798A (en) | Methods for purification of arylsulfatase a. | |
PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
PE20121033A1 (en) | RECOMBINANT PRODUCTION OF PEPTIDES | |
NO20072661L (en) | Purification of glycopeptides | |
MX2019007995A (en) | Novel polypeptide and method for producing imp using same. | |
WO2015021423A3 (en) | Purification of chimeric fviii molecules | |
NZ781138A (en) | Anti-vegf protein compositions and methods for producing the same | |
IN2014CH00378A (en) | ||
MX2016013416A (en) | Novel purification process of gonadotropin. | |
WO2020186155A3 (en) | Synthetic neuromodulatory peptides | |
ZA202206835B (en) | Method for purifying biologically active peptide by using protein a affinity chromatography | |
ES2090840T3 (en) | PURIFICATION PROCEDURE OF A HYDROFLUOROALCAN. | |
MX2022007679A (en) | Purified compositions of enteroviruses and methods of purification with glutathione affinity chromatography. | |
UA85741C2 (en) | Method the production of the immunoglobulin | |
WO2020164721A8 (en) | Chromatographic purification of at least one enzyme selected from the group consisting of collagenase type i, collagenase type ii, neutral protease, and clostripain | |
MX2022002628A (en) | Fusion proteins and uses thereof. | |
BR112021024417A2 (en) | Methods for removing unwanted components during multi-stage chromatographic processes | |
PT1558354E (en) | Using amines, amino acids or amino acid esters as mobile phase modifiers in chromatography | |
ATE395360T1 (en) | NEW METHOD FOR PURIFYING HUMAN GROWTH HORMONE | |
MX2021016092A (en) | Methods for protein purification. | |
WO2023205752A3 (en) | Ephrin ligand mimetic peptides for the treatment of neurodegenerative diseases |